Church & Dwight Co., Inc. Q4 FY2025 earnings call

Key managerial messages include: growth across divisions in 2025, strong tariff response and mitigation, portfolio changes like divestitures and shutdowns, a strong balance sheet, focus on Evergreen model with pillars like growing ARM & HAMMER from $2B to $3B, oral care expansion via TheraBreath, scaling international business, innovation and marketing spend supporting brands, and creation of a specialty hair and skin pod for brands like Hero, BATISTE, and Touchland.

In 2025, Church & Dwight grew faster than categories across all 3 divisions. 4 of 8 power brands grew share, with Hero and TheraBreath growing double digits. They acquired Touchland, divested Spinbrush and Vitamins, and shut down Flawless and Showerheads. ARM & HAMMER brand was #1 in wash loads. TheraBreath had 12% household penetration. International business saw 5.5% organic growth in 2025.

Organic growth for 2026 is expected to be in the range of 3%-4%. Reported sales are projected to be between $6.1B-$6.2B. Gross margin improvement of about 100 basis points is anticipated. EPS outlook is 5%-8%, with cash flow expected at $1.15B. A 4.2% dividend increase was announced for 2026.

Risks include category deceleration, weak consumer sentiment, initial tariff exposure, and competition/promotional challenges in some categories.

Q: On ARM & HAMMER growth internationally and the specialty teams A: Bulk of ARM & HAMMER growth is domestic but has global potential; specialty teams like Accelerator Group for key brands Q: On Vitamins business and resource allocation A: Selling Vitamins freed up resources for growth in other areas Q: On Touchland international expansion and brand exclusivity A: Touchland international expansion going well, careful with channel selection to maintain brand cache Q: On guidance and inventory destocking A: U.S. growth 3%, international 8%, SPD 5%; inventory destocking impacted 2025 but accounted for in 2026 guidance Q: On promotions and price mix A: Brands matter, promotional levels expected to drift back to normalcy, ARM & HAMMER gaining share despite competition Q: On gross margin potential A: Confident in gross margin expansion, though world changes rapidly Q: On Touchland distribution and line extensions A: Touchland distribution carefully managed, line extensions not commented on yet Q: On ARM & HAMMER $2B to $3B goal and TheraBreath paste A: ARM & HAMMER $2B to $3B goal has pillars including core growth, in-house licensing, new categories; TheraBreath paste marketed to leverage rinse consumer base Q: On value consumer and international growth A: Confident in capitalizing on value-seeking consumers while managing margins; international growth pace to offset U.S. challenges